Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis
about
Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectivesBiomimetic and synthetic interfaces to tune immune responsesTempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cellsThe spleen in local and systemic regulation of immunityAntigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 DiabetesRestoring immune tolerance in neuromyelitis optica: Part IManipulating regulatory T cells: a promising strategy to treat autoimmunityToward beta cell replacement for diabetesApoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunityNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data?Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbiditiesRestoring the balance: immunotherapeutic combinations for autoimmune diseaseDefining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.Preemptive donor apoptotic cell infusions induce IFN-γ-producing myeloid-derived suppressor cells for cardiac allograft protection.GM-CSF-neuroantigen fusion proteins reverse experimental autoimmune encephalomyelitis and mediate tolerogenic activity in adjuvant-primed environments: association with inflammation-dependent, inhibitory antigen presentation.Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spreadPreemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection.The role of dendritic cells in tissue-specific autoimmunity.Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantationCo-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis.MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity.Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.T cells in the control of organ-specific autoimmunityInfusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in MiceMechanisms of immunological tolerance in central nervous system inflammatory demyelination.Harnessing nanoparticles for immune modulationEngineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.Controlled release strategies for modulating immune responses to promote tissue regenerationTargeting Treg signaling for the treatment of autoimmune diseasesCutting Edge: Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes.Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersAutoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients.Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy.Immune Tolerance for Autoimmune Disease and Cell TransplantationBiodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.Exploiting apoptosis for therapeutic tolerance induction.CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
P2860
Q26748984-C1688896-AD04-466A-83C8-A8BEC642D3DAQ26801229-53825AE8-A526-4E81-9180-F68BFDBF71ACQ26851647-1B02C6C1-49C8-4950-998F-BD15C1F5DEE5Q27025001-197B20E0-30FA-4412-9EA6-088AD8B8713AQ27687250-470BFC67-31CE-4A42-B938-8EB51C5F0E18Q28071490-B0B536C6-40C0-4FCD-B013-1BF89363A0C4Q28072382-6507675C-F8A8-4D68-ACC0-482D96FB909CQ28083298-606E4688-450D-48E1-A230-0B5E4AB01323Q28083650-674D158D-987B-4A53-A08A-C4CD15A41FC6Q28385358-7749B68C-687C-4E92-959B-AD1A66D37785Q30699740-13809259-54F6-4A0D-AEB8-6290F5272949Q30723942-F5A4DEB3-3E58-422A-8C29-6E6D785F672DQ31142266-E2CFAF9B-A06F-432F-B908-B3610AFF799CQ33555986-5CCA1074-91A6-4FA3-A26B-F7BCDD5BD370Q33687644-A4523678-A5DD-4A8A-B9DE-4DCBBBF1D2E7Q33850216-5EB02D93-29D8-462A-8CF5-ED15C307F914Q34065039-158ED1F7-A772-4E4D-9A08-844D985E5C3AQ34364686-4932A617-F621-4801-87FD-BF71DF29DE82Q34389486-4FEAA44D-CB76-4857-B359-92742D42B14CQ34422017-C585ED8F-2F0E-407B-85E7-227EDA44CA72Q34506806-A4680ACC-F4EC-4BB8-BF61-07F9D62D8FBDQ35318380-383F5A5F-725B-498B-A21B-87CB00F66E14Q35601282-19D34DDF-79D1-4D9C-A01F-93258B0CA137Q35665104-B88E8797-D987-494A-956C-8C6E80845E5AQ35836118-A2CE4B1D-A8B0-46B5-A535-D873954C2530Q35894465-4F94BE06-E2EA-4622-ADF0-9F6B94BFA026Q36095922-9DA04013-BF58-4F09-8B49-229BB6EC091CQ36154772-B0C81201-CDC4-462B-95A7-FCEA30768E12Q36284750-02727AAE-4AC3-43B4-897C-F66F7E26C123Q36307642-04903651-538B-4AB0-857B-7D94E63DD3ECQ36372616-0941035B-6FEF-4237-AEB4-F1B202036A02Q36387060-B753D1F4-95B0-4448-A094-D71C519FFB02Q36484394-339860BD-C30E-4EA2-8BD2-D946EEAA5E0CQ36854682-D5EBB176-A12A-404D-8BA9-1B1B4F2D66AAQ36894072-64112786-AD9F-4BFA-ADBE-68BF3C633CD1Q37008459-73213F95-4DC4-46A3-8CDC-8DBA5E365214Q37099107-6F8CA32B-5DCE-4DAE-AD88-468D868A5FB3Q37173058-7D6AEFCA-F4D4-4C24-9ABC-53A200CDA16BQ37353657-3FE110CA-7A8B-4462-B29E-5B3863A1F0F0Q37368151-17C06CD7-2496-4D62-8205-833750F551C4
P2860
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis
@en
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis.
@nl
type
label
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis
@en
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis.
@nl
prefLabel
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis
@en
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis.
@nl
P2093
P2860
P1476
Antigen-specific tolerance by ...... 1 trial in multiple sclerosis
@en
P2093
Andreas Lutterotti
Andreas Sputtek
Christian Schulze
Christoph Heesen
Jan-Patrick Stellmann
Klarissa H Stürner
Maxim Bester
Mireia Sospedra
Petra Breiden
Roland Martin
P2860
P304
P356
10.1126/SCITRANSLMED.3006168
P407
P577
2013-06-01T00:00:00Z